Table 1.
Participant Demographics and Reported Symptoms
| Variable | COVID-19 Diagnosis Status |
||
|---|---|---|---|
| Confirmed (n = 2) | Suspected (n = 7) | Negative (n = 19) | |
| Age, years, M (SD) | 51.5 (7.8) | 28.3 (7.4) | 43.8 (18.6) |
| Ethnicity, n (%) | |||
| Hispanic | 1 (50.0) | 3 (42.9) | 9 (47.4) |
| Non-Hispanic | 1 (50.0) | 4 (57.1) | 10 (52.6) |
| Race, n (%) | |||
| White | 2 (100.0) | 6 (85.7) | 12 (63.1) |
| Black | 0 (0.0) | 1 (14.3) | 5 (26.3) |
| Asian | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Declined | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Symptoms, n (%) | |||
| Cough | 2 (100.0) | 7 (100.0) | 11 (57.9) |
| Fever | 1 (50.0) | 4 (57.1) | 2 (10.5) |
| Headache | 2 (100.0) | 7 (100.0) | 7 (36.8) |
| Shortness of breath | 2 (100.0) | 5 (71.4) | 8 (42.1) |
| Fatigue | 2 (100.0) | 6 (85.7) | 7 (36.8) |
| Muscle aches | 2 (100.0) | 5 (71.4) | 5 (26.3) |
| Loss of smell | 1 (50.0) | 4 (57.1) | 0 (0.0) |
| Loss of taste | 1 (50.0) | 3 (42.9) | 0 (0.0) |
| Sore throat | 1 (50.0) | 4 (57.1) | 6 (31.6) |
| Congestion | 0 (0.0) | 5 (71.4) | 8 (42.1) |
| Chills | 2 (100.0) | 4 (57.1) | 2 (10.5) |
| Runny nose | 0 (0.0) | 0 (0.0) | 5 (26.3) |
| Nausea/vomiting | 1 (50.0) | 2 (28.6) | 5 (26.3) |
| Back pain | 0 (0.0) | 0 (0.0) | 2 (10.5) |
| Diarrhea | 1 (50.0) | 1 (14.3) | 5 (26.3) |
| Insomnia | 0 (0.0) | 0 (0.0) | 2 (10.5) |
| Rash | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Palpitations | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Earache | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Indigestion | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| Constipation | 0 (0.0) | 0 (0.0) | 1 (5.3) |
| 0 (0.0) | 0 (0.0) | 1 (5.3) | |
Note. Postvaccine side effects were not included in the table for participants who had received the COVID-19 vaccine before their interview.